Table 2 Comparison of the participants’ baseline inflammatory markers and clinical outcomes

Inflammatory markers

 Interleukin-6 (pg/ml)

6.34 ± 3.15

6.39 ± 3.34

6.28 ± 3.00

0.123^a

0.903

 Fibrinogen (mg/dl)

417.3 ± 76.3

424.5 ± 79.0

410.0 ± 74.5

0.650^a

0.519

 Leucocytes (× 10³/uL)

8.48 ± 3.88

7.60 ± 4.23

9.36 ± 3.36

1.591^a

0.118

 Neutrophils (× 10³/uL)

5.69 ± 3.68

5.38 ± 3.94

5.99 ± 3.45

0.575^a

0.568

 Lymphocytes (× 10³/uL)

2.87 ± 2.21

3.02 ± 2.78

2.71 ± 1.51

0.474^a

0.638

 Monocytes (× 10³/uL)

0.67 ± 0.34

0.63 ± 0.32

0.72 ± 0.35

0.968^a

0.338

Clinical outcomes

 Motor impairment (SMSNIHSS)

4.50 (4.0–5.0)

5.0 (4.0–5.0)

4.0 (4.0–5.0)

248.0^b

0.360

 Physical disability (mRS)

4.0 (4.0–5.0)

5.0 (4.0–5.0)

4.0 (3.0–5.0)

215.5^b

0.105

 Functional independence (MBI)

65.0 (44.0–72.7)

66.5 (46.2–76.5)

60.0 (33.0–72.5)

250.0^b

0.433

 Depression (HADS-D)

9.0 (7.0–12.0)

8.5 (7.0–12.0)

9.0 (7.2–11.7)

275.5^b

0.796

 Anxiety (HADS-A)

10.0 (7.0–12.0)

9.5 (6.2–11)

10.0 (7.0–12.0)

246.0^b

0.383

 Cognition (MoCA)

15.0 (10.2–19.7)

14.0 (9.2–21.0)

16.0 (11.2–19.7)

278.0^b

0.836